ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT

Yalçınkaya Y., Amikishiyev S., Aliyeva N., Artım Esen B., Bingöl Z., Okumuş N. G., ...More

7 th Systemic Sclerosis Congress, 10 - 12 March 2022, pp.1

  • Publication Type: Conference Paper / Summary Text
  • Page Numbers: pp.1
  • Istanbul University Affiliated: Yes